Bibliographic Details
| Title: |
Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer. |
| Authors: |
Chow, Frances, Lamoureux, François, Moriceau, Gatien |
| Source: |
Frontiers in Immunology; 2024, p1-2, 2p |
| Subject Terms: |
T-cell exhaustion, THERAPEUTICS, NON-small-cell lung carcinoma, AP-1 transcription factor, COMBINATION drug therapy |
| Abstract: |
The editorial in Frontiers in Immunology discusses the challenges posed by mutation-driven cancers and the need for innovative therapeutic strategies to combat them. The research topic focuses on preclinical studies, target-based mechanisms for combination therapies, and approaches to overcome resistance to current treatments. The editorial highlights a study on predicting pancreatic cancer prognosis based on KRAS mutation status, as well as reviews on the potential of antibody-drug conjugates for lung cancer and FGFR-targeting therapies for urothelial carcinoma. The authors emphasize the importance of ongoing research in developing next-generation therapeutics to address mutation-driven cancers. [Extracted from the article] |
|
Copyright of Frontiers in Immunology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
